Successful off-label sulfonylurea treatment of neonatal diabetes mellitus due to chromosome 6 abnormalities.

Details

Serval ID
serval:BIB_6D291E420568
Type
Article: article from journal or magazin.
Collection
Publications
Title
Successful off-label sulfonylurea treatment of neonatal diabetes mellitus due to chromosome 6 abnormalities.
Journal
Pediatric diabetes
Author(s)
Garcin L., Kariyawasam D., Busiah K., Fauret-Amsellem A.L., Le Bourgeois F., Vaivre-Douret L., Cavé H., Polak M., Beltrand J.
ISSN
1399-5448 (Electronic)
ISSN-L
1399-543X
Publication state
Published
Issued date
06/2018
Peer-reviewed
Oui
Volume
19
Number
4
Pages
663-669
Language
english
Notes
Publication types: Case Reports ; Journal Article ; Review
Publication Status: ppublish
Abstract
Chromosome 6 abnormalities such as paternal uniparental isodisomy, paternal 6q24 duplication, and maternal DMR (differentially methylated region) hypomethylation are a common cause of transient neonatal diabetes mellitus (TNDM). Oral sulfonylurea (SU) is used off-label to treat permanent neonatal diabetes mellitus owing to potassium channel mutation but has not been evaluated in TNDM. Our objective was to evaluate the efficacy and safety of SU therapy in chromosome 6-related TNDM. Description of 3 case reports and literature review was the subject of the study. SU therapy was successful in 2 patients (initiated during neonatal life in 1 patient and during relapse in the other) but failed in the other despite the use of high dosage. The literature review identified 11 cases of patients with chromosome 6-related TNDM treated with SU, including 4 treated before remission and 7 after the relapse. SU therapy was consistently effective, although 4 patients treated after the relapse required multiple oral medications. None of the patients needed associated insulin therapy. No side effects of SU or complications of diabetes were reported. SU seems effective and safe in chromosome 6-related TNDM treatment when used to treat the initial episode of diabetes or the relapse. It improves patients' and families' quality of life. SU is available only as oral tablets. A pediatric dosage form would facilitate the treatment of neonates and infants.
Keywords
Chromosome Aberrations, Chromosomes, Human, Pair 6/genetics, Diabetes Mellitus/drug therapy, Diabetes Mellitus/genetics, Female, Humans, Hypoglycemic Agents/therapeutic use, Infant, Newborn, Infant, Newborn, Diseases/drug therapy, Infant, Newborn, Diseases/genetics, Male, Off-Label Use, Sulfonylurea Compounds/therapeutic use, Treatment Outcome, chromosome 6, monogenic diabetes, sulfonylureas, transient neonatal diabetes
Pubmed
Web of science
Create date
28/02/2020 17:02
Last modification date
02/04/2020 14:02
Usage data